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Background: An abundance of tumor-associated macrophages has been shown to be an independent
prognostic factor for a poor prognosis of human breast cancer (BC). Adipose tissue accounts for the
largest proportion of the breast and has also been identi ed as an independent indicator of poor survival
in BC. This study aims to elucidate, if the in uence of adipose tissue in BC might be mediated by
macrophages. The roles of macrophages in the breast tumor-stroma (breast tumor stroma macrophages,
BTSM) and macrophages in the surrounding adipose tissue (breast adipose tissue macrophages, BATM)
were explored separately.
Methods: 298 BC tissue samples were analyzed immunohistochemically. The number of macrophages
was detected by CD68+ staining. The quantity of BATMs and BTSMs was correlated to clinical and
pathological parameters as well as to disease free survival (DFS) and overall survival (OS).
Results: The amounts of BATMs and BTSMs strongly correlated with each other (r = 0.5, p < 0.001). The
quantity of BTSMs, but not of BATMs, was signi cantly associated with the BC molecular subtype (p <
0.001) and all triple negative BC tumors contained high amounts of BTSMs. BATMs were negatively
associated with DFS (p = 0.0332). Both BATMs (p < 0.001) and BTSMs (p = 0.021) were negatively
associated with OS in the Kaplan-Meier analysis, but only BATMs remained an independent factor in the
multivariate Cox-regression analysis (HR = 4.464, p = 0.004). Combining prostaglandin E2 receptor 3
(EP3)-expression and the quantity of BATMs, a subgroup with an extremely poor prognosis could be
identi ed (median OS 2.31 years in the “high BATMs/low EP3” subgroup compared to 11.42 years in the
most favorable “low BATMs/high EP3” subgroup, p < 0.001).
Conclusion: Our  ndings suggest that BTSMs and BATMs seem to be involved differently in BC. Breast
adipose tissue might contribute to the aggressiveness of BC via BATMs, which were independently
associated with BC survival. BATMs’ role and occurrence might be functionally dependent on EP3, as a
combination of both factors was strongly associated with survival. Targeting BATMs – eventually in
combination with targeting the EP3-pathway – might be promising for future therapies.
Background
Macrophages play an important role in regulating the migration and invasion of breast cancer (BC) cells
and in promoting BC metastasis (1). Clinical studies have shown that the abundance of tumor-associated
macrophages (TAMs) in BC tissue is an independent prognostic factor for a poor prognosis: high levels
of TAMs in BC were associated with an impaired disease free survival (DFS) and overall survival (OS) (2,
3). Macrophages can be subdivided according to their phenotype into the two subgroups of M1
(“classically activated”) and M2 (“alternatively activated”) macrophages (4–7). M1 macrophages are
usually activated by monocytes due to their induction by bacteria or its product lipopolysaccharide (LPS).
M1 macrophages show a high antigen presentation ability and high secretion levels of interleukin-12 (IL-
12) (4–8). M2 macrophages can be activated by monocytes due to their induction by interleukin-4 (IL-4),
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interleukin-6 (IL-6), macrophage colony stimulating factor (MCSF), or prostaglandin E2 (PGE2) (4–7, 9,
10). Initially, M1 macrophages were characterized as pro-in ammatory, while M2 macrophages were
described to regulate the repair of tissues and the resolution phase of in ammation (11). In the case of
immune homeostasis, the two sub-populations are assumed to be in equilibrium. Today, it is well known
that their functions show wider overlapping (12, 13). In immunohistochemical staining, macrophages can
be detected by speci c CD molecules. CD68 is the most common marker for monocytes and
macrophages independent of their polarization (14–16). M2 macrophages can be detected in tissues
using the speci c marker CD163 (14, 15, 17). In BC, high levels of tumor in ltrating CD163 + 
macrophages have been associated with higher proliferation rates, lower tumor cell differentiation, and a
lack of hormone receptor (HR) expression (HR negativity) (18). Additionally, more CD163 + macrophages
could be detected in triple-negative breast cancer (TNBC) than in other BC subtypes (19, 20). PGE2, which
contributes to M2 polarization, is a tissue hormone with various effects that also exerts direct effects on
tumor cells. The role of PGE2 and its receptors prostaglandin E2 receptor 1–4 (EP 1–4) has been widely
investigated in BC (21, 22). EP2 and EP4 are the best evaluated receptors and are mainly assumed to be
negative prognostic factors (21, 23), while EP1 and EP3 are less well understood and have shown tumor-
suppressive effects (24, 25).
TNBC is the biological subgroup of BC lacking the expression of the HRs, estrogen receptor (ER) and
progesterone receptor (PR) and not showing an ampli cation of human epidermal growth factor receptor
2 (HER2)(26). TNBC represents approximately 15–20% of all BC cases (27) and is considered to be more
aggressive, showing a poorer prognosis and more often visceral metastases than other subtypes of BC
(28). As the classical target structures are missing, no targeted therapies are available in TNBC so far.
Only recently, a milestone in TNBC therapy has been achieved through the demonstration of the bene cial
effect of immune therapies (29).
The largest proportion of breast tissue consists of adipose tissue (30). Recent studies have shown that
adipose tissue from grafts can potentially promote or accelerate the development or local recurrence of
subclinical breast tumors (31). Zhu et al.(32) summarized the association of adipose cells and BC cells
as follows: (i) in ltrating BC cells can greatly affect the surrounding adipose cells; (ii) adipose cells
around the tumor show a modi ed phenotype and speci c biological characteristics and (iii) surrounding
adipose cells modify BC cells characteristics and their phenotype leading to a more aggressive behavior.
Even after adjusting for body mass index (BMI), age, and menopausal status, fatty breasts (very low
density, VLD) are still an independent indicator of poor survival in BC (33). Furthermore, BC in fatty
breasts usually contains high levels of M2-like macrophages, which might reduce local in ammation,
contribute to tumor promotion and lead to an impaired survival (33). However, the localization (in the
tumor or in the tumor surroundings) and the exact phenotype of these macrophages have not yet been
fully clari ed.
A further feature found in adipose tissue, which is considered to be a hallmark of the proin ammatory
process in adipose tissue, are the so-called crown-like structures (CLS, recently reviewed by Faria et.al
(34)) CLS consist of hypertrophied, necrotic adipocytes (that need to be resorbed) surrounded by adipose
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tissue M1 macrophages (35–38). CLS might promote BC and might contribute to the fact that obese
women are more likely to be diagnosed with larger and higher-grade BC and have higher incidence of
metastases than lean individuals (39). In obese and overweight patients, more adipose cell death
(represented by a higher number of CLS) resulting in a release of free fatty acids occurs, and an
in ltration of pro-in ammatory M1 macrophages maintaining the exacerbated in ammatory state has
been shown (40). In adipose tissue of lean individuals M2 predominate M1 macrophages (M2:M1 ratio
4:1), while in obese individuals, much more M1 than M2 macrophages can be detected (M2:M1 ratio
24:65) (41–43). An increased number of CLS has been shown in breast adipose tissue from especially
obese BC patients, which has been related to high recurrence rates and poor survival (44).
However, what makes breast adipose tissue contributing to BC promoting events - not only in obese BC
patients but probably also in lean individuals - remains an intriguing question to be solved. The data
mentioned above indicates that the quantity of macrophages in the adipose tissue of BC might be
important. This study aims to elucidate the role of adipose tissue in BC development in general.
Therefore, the crosstalk between adipocytes, macrophages and BC cells was evaluated in an unselected
cohort of primary BC patients, independent of a pre-set condition of overweight or obesity. Furthermore, to
clarify the role of the localization of the macrophages, we analyzed macrophages in ltrating in the breast
adipose tissue (breast adipose tissue macrophages, BATMs) and in the breast tumor-stroma tissue
(breast tissue stroma macrophages, BTSMs) separately. The quantity of BATMs and BTSMs was
correlated to clinical and pathological parameters as well as to survival.
Methods
Human tissue samples
In this study, 320 consecutive patients who underwent surgery for BC from 2000 to 2002 at the
Department of Gynecology and Obstetrics, Ludwig-Maximillian’s-University of Munich, Germany and of
whom tumor tissue was still available were primarily included. In the further analyses, only cases with a
diagnosis of sporadic BC and without family history for BC were included (n = 306). Patients with primary
distant metastases (n = 6) and patients with only Ductal carcinoma in Situ (DCIS) but without invasive
BC (n = 2) were excluded from further analyses. So, 298 patients were included in the  nal analyses. The
Institute of Pathology, Ludwig-Maximillian’s-University of Munich, assigned the tumor grading (according
to the Elston-Ellis system); tumors were classi ed according to the American Joint Committee on Cancer
(AJCC) TNM staging system. The surrogate intrinsic BC subtype (the following  ve groups) was de ned
by immunohistochemistry: Luminal A-like (ER/PR positive, HER2 unampli ed, ki67 less than 14 %),
Luminal B-like (ER/PR positive, HER2 unampli ed, ki67 more than 14 %), Basal-like/Triple negative (ER
and PR negative, HER2 unampli ed), HER2 ampli ed Luminal-like (ER/PR positive, HER2 ampli ed) and
HER2 ampli ed non Luminal-like (ER/PR negative, HER2 ampli ed). We further included the expression of
EP3 (measured immunohistochemically and quanti ed by the immune reactive score, IRS), which has
already been performed by our team previously (24) as well as further prognostic factors previously
described by our group into the analysis. Patient data regarding patient age, HR status, HER2-
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ampli cation, metastasis, local recurrence, progression and survival were retrieved from the Munich
Cancer Registry. DFS and OS were statistically analyzed after an observation period of up to 12 years.
Immunohistochemistry
Formalin- xed tissue slides were embedded in para n wax for immunohistochemistry. The samples were
de-para nized in xylol for 20 min and rinsed in 100% ethanol. Methanol/H2O2 incubation for 20 min was
performed to inhibit endogenous peroxidase reaction. Afterwards, the specimens were rehydrated in a
descending alcohol gradient, starting with 100% ethanol and ending with distilled water. The samples
were cooked in a pressure cooker, containing a sodium citrate buffer (pH = 6.0), which consisted of 0.1
mM citric acid and 0.1 mM sodium citrate in distilled water. Subsequently, the samples were washed in
PBS twice and incubated with a blocking solution (reagent 1, ZytoChem Plus HRP Polymer System
(Mouse/Rabbit), Zytomed, Berlin, Germany) for 5 min. Then, an incubation with the primary antibody was
performed with each section for 16 h at 4 °C. Primary anti-CD68-antibody (Rabbit IgG polyclonal, Sigma
Aldrich, St. Louis, MO, USA) was used for tissue slides staining. Following every subsequent step, the
samples were washed twice in PBS (pH = 7.4). “Post block” (reagent 2) for 20 min and HRP-Polymer
(reagent 3) for 30 min were applied. The chromogen-substrate staining was carried out using the Liquid
DAB+ Substrate Chromogen System (Dako Scienti c, Glostrup, Denmark) for 2 min. The reaction was
stopped by applying distilled water. Finally, the tissue samples were counterstained with hemalum for 2
min and blued in tap water. The specimens were dehydrated in an ascending alcohol gradient and cover
slipped with Eukitt® quick hardening mounting medium (Sigma Aldrich, St. Louis, MO, USA). Placenta
tissue served as positive control and negative control. All slides were analyzed using the microscope Leitz
Wetzlar (Wetzlar, Germany; Type 307-148.001 514686).
Quantity of macrophages
CD68 positivity is an indicator for all macrophages (33). The immunohistochemical staining for
macrophages was performed as described above. 298 adequately CD68-immunostained tissue sections
were available for analysis. CD68 is located in the cytoplasm of the macrophages; the positive staining is
brownish-yellow or brown particles (Figure1 a-1d). The staining intensity of CD68 in the BC tissue
samples was limited to the number of macrophages at each respective site. Cancer cells did not express
CD68. The tumor cells which were pleomorphic and atypical with large nuclei and nucleoli were easy to
distinguish from the macrophages. Other cells like  brocytes and adipocytes were also not stained with
CD68. Therefore, we directly counted the CD68 positive cells and from there concluded the number of
macrophages. Three investigators counted the number of macrophages in four views of each IHC slide,
separately in the breast tumor-stroma section and the breast adipose tissue section. The average value
represented the quantity of macrophages in the respective sections. The macrophages in the breast
tumor-stroma section were de ned as breast tumor-stroma macrophages (BTSMs), the macrophages in
the adipose tissue around the tumor were named breast adipose tissue macrophages (BATMs). The
levels of BTSMs and BATMs were categorized as either low or high and the resulting groups were named
“BTSMs/BATMs-high” and “BTSMs/BATMs-low”. The cut-off values for the categorization were
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determined using receiver operating characteristic curve (ROC-curve) analysis based on OS and DFS.
Slides with a BATMs quantity ≤ 9.5 were de ned as “BATMs-low” and a BATMs quantity > 95 was
de ned as “BATMs-high”. A BTSMs quantity ≤ 4.5 was de ned as “BTSMs-low” and a BTSMs quantity >
4.5 was de ned as “BTSMs-high”. Both parameters, the total quantity of BTSMs and BATMs as
continuous variables as well as the categorized variables “BATMs/BTSMs-high” and “BATMs/BTSMs-
low” were compared to known clinical and pathological parameters and further prognostic factors
previously determined in this collective by our group. Only the categorized variables were used to analyze
the in uence of BATMs and BTSMs on OS or DFS. 
Statistics
IBM SPSS software version 26 was used to analyze data. Microsoft Excel 2017 was used for illustrations.
P-values <0.05 were considered statistically signi cant. Chi square test, Mann–Whitney-U-test and
Kruskal-Wallis test were used to calculate the differences between the parameters. Bivariate correlations
between study variables were calculated using the Spearman’s rank correlation coe cient. Univariate
survival analyses were calculated with Cox’s model, and survival curves were plotted with the Kaplan–
Meier method. Cox’s model was used also for multivariate survival analyses. In the multivariate analyses,
we included the quantity of BATMs, the quantity of BTSMs, patient age and further variables with a p-
value < 0.05 in univariate analyses.
Results
Clinical and pathological characteristics of the BC cohort and quanti cation of BATMs and BTSMs
The distribution of clinical and pathological parameters in our total cohort and in the BATM/BTSM-high
and BATM/BTSM-low subgroup is displayed in Table 1. Not all pathological parameters could be
obtained from every patient, which is why the numbers of patients in some subgroups is lower than the
number of all cases analyzed. In the overall cohort, 75.8% of all patients were older than 50 years. Most
tumors were ER positive (80.9%), PR positive (57.0%), did not show an HER2 ampli cation (88.3%) and
had low proliferation rates (ki-67 ≤ 14%: 56%). 55.7% of all tumors were de ned as luminal A-like, 20.1%
were luminal B-like and 12.8% were TNBC. 8.1% of all patients had HER2 ampli ed luminal-like BC and
only 2.7% were HER2 ampli ed non-luminal like. Tumor grading was only available in 54.3% of all cases,
so this parameter must be regarded with limited reliability (Table 1).
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123(75.0) 41(25.0) 31(17.2) 149(82.3)
  < 50 years 72
(24.2)
47(83.9) 9(16.1) 11(16.7) 51(77.3)





99(78.0) 28(22.0) 37(26.8) 101(73.2)
  Luminal B-like 60
(20.1)
39 (79.6) 10(20.4) 2(3.8) 50(96.2)
  Triple negative 38
(12.8)
16(66.7) 8(33.3) 0(0.0) 30(100.0)
  HER2 ampli ed
luminal-like
24 (8.1) 11(78.6) 3(21.4) 1(6.3) 15(93.7)
  HER2 ampli ed non
luminal-like
8 (2.7) 5 (83.3) 1(16.7) 2(33.3) 4(66.7)
  Chi square p value   0.779 0.000011***
Grading G1 15 (5) 7(63.6) 4(36.4) 4(30.8) 9(69.2)
  G2 103
(34.6)
56(77.8) 16(22.2) 12(15.0) 68(85.0)
  G3 44
(14.8)
25(78.1) 7(21.9) 7(20.6) 27(79.4)
  Chi square p value   0.594 0.337
Tumor focis Unifocal 161
(54.0)






  Chi square p value   0.272 0.554
Tumor size pT1 194
(65.1)
114(80.3) 28(19.7) 31(20.0) 124(80.0)
  pT2 87
(29.2)

























  pT3 4 (1.3) 1(33.3) 2(66.7) 0(0.0) 3(100.0)
  pT4 13 (4.4) 6(60.0) 4(40.0) 3(25.0) 9(75.0)






91(77.8) 26(22.2) 23(17.6) 108(82.4)
pN1 124
(41.6)
73(76.8) 22(23.2) 18(17.6) 84(82.4)
  pN2 4 (1.3) 1(33.3) 2(66.7) 0(0.0) 4(100.0)
  Chi square p value   0.224 0.796
ER status Negative 57
(19.1)
28(75.7) 9(24.3) 4(8.9) 41(91.1)
  Positive 241
(80.9)
142(77.6) 41(22.4) 38(19.3) 159(80.7)
  Chi square p value   0.799 0.096
PR status Negative 128
(43.0)
67(75.3) 22(24.7) 20(25.0) 80(75.0)
  Positive 170
(57.0)
103(78.6) 28(21.4) 22(15.5) 120(84.5)
  Chi square p value   0.561 0.362
HER2 status Negative 263
(88.3)
154(77.4) 45(22.6) 39(17.8) 180(82.2)
  Positive 33
(11.1)
16(76.2) 5(23.8) 3(13.0) 20(87.0)





100(78.1) 28(21.9) 37(26.6) 102(73.4)
  > 14% 60
(20.1)
39(79.6) 10(20.4) 2(3.8) 50(96.2)
  Chi square p value   0.832 0.001**
Expression
of EP3









































  Chi square p value   0.051 0.208
BATMs, Breast adipose tissue macrophages; BTSMs, Breast tumor-stroma macrophages; ER,
Estrogen receptor; PR, Progesterone receptor; HER2, Human epidermal growth factor receptor 2; EP3,
Prostaglandin E receptor 3 .
 
A successful staining of BATMs was achieved in 220/298 patient samples (due to technical issues).
22.7% of these cases showed high populations of BATMs while the remaining 77.3% showed a low
amount of BATMs (Table 1). BTSMs could be stained in 242/298 samples. High amounts of BTSMs were
detected in 82.7% of these cases and a low quantity of BTSMs in 17.3% (Table 1). The quantities of
BATMs and BTSMs correlated strongly with each other (r = 0.5, p = 2.98E-15) (Fig. 1e).
Association of BATMs and BTSMs with clinical and pathological parameters in BC
The distribution of clinical and pathological parameters in the BATMs/BTSMs high and low subgroups is
displayed in Table 1; signi cant associations of BATMs/BTSMs with clinical and pathological
parameters in Fig. 1.
The subgroups did not correlate to patient age, however, the total quantity of BATMs was signi cantly
higher in patients older than 50 years compared to younger patients (p = 0.0325, Fig. 1a, 1b, 1f). No
further correlations of BATMs and clinical or pathological parameters could be found, neither when
analyzing the subgroups, nor when regarding the total quantity of BATMs.
The BTSMs-subgroup correlated strongly to the molecular subtype (p = 0.000011, Table 1). All (100%)
TNBC cases belonged to the “BTSMs-high” subgroup. The “BTSMs-high” subgroup was also strongly
represented in luminal B-like tumors – in both HER2 negative and HER2 positive cases. Luminal A like
tumors showed high BTSMs populations less frequently, which was signi cantly different to the amount
in TNBC in a pairwise comparison (p = 0.0005, Fig. 1 g). The BTSMs-high subgroup was least represented
in HER2 positive non-luminal cases, however, as this subgroup contained only 6 cases, this result must be
regarded with limited reliability. Not only when grouping the quantity of BTSMs into a high and low
population, but also when comparing the absolute quantity of BTSMs between the different molecular BC
subtypes, a signi cant association could be found (p = 0.0003, Fig. 1 g). As the molecular subtypes are
de ned by surrogate immunohistochemical parameters, these results were consistent when not the
subtype but the single parameter was analyzed: high populations of BTSMs occurred more frequently in
the ki-67 > 14% group (96.2%) than in cases with an expression of ki-67 ≤ 14% (73.4%, p = 0.001) (Table
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1). The absolute quantity of BTSMs in ER negative patients was signi cantly higher than in ER positive
patients (p = 0.002, Fig. 1 h). No correlations between the amount of BTSMs and PR status, HER2 status
or other clinical and pathological parameters was found (Table 1).
Both BATMs and BTSMs were negatively associated with OS
Patients in the BATMs-high (HR = 2.483, p = 0.000401, Fig. 2a) as well as in the BTSMs-high (HR = 2.445,
p = 0.021, Fig. 2b) subgroup showed a signi cantly impaired OS compared to the respective “low”
subgroup. Median OS was 7.48 years in the BATM-high population (n = 50) while the median was not
reached (NR) in our follow up period in the BATM-low (n = 170) population. 75% OS was 6.49 years in the
BTSM-high (n = 200) versus 11.64 years in BTSM-low (n = 42) subgroup. Median OS was not reached in
the BTSM-high as well as in the BTSM-low subgroup.
In a subgroup analysis, a high amount of BATMs was a negatively associated with OS independent of
tumor foci (in unifocal tumors: supplementary Fig. 1a, n = 117, p = 0.006 and in multifocal and
multicentric tumors: supplementary Fig. 1b, n = 103, p = 0.025) and independent of PR status (in PR
positive tumors: supplementary Fig. 1d, n = 131, p = 0.041 and in PR negative tumors, supplementary
Fig. 1e, n = 89, p = 0.005). High amounts of BATMs were also negatively associated with OS in the
subgroups of patients aged older than 50 years (supplementary Fig. 1c, n = 164, p = 0.001), in Luminal A-
like tumors (supplementary Fig. 1f, n = 127, p = 0.001), in TNBC (supplementary Fig. 1 g, n = 24, p = 0.049),
in tumors smaller than 2 cm in size (supplementary Fig. 1 h, n = 142, p = 0.008), in BC patients with
negative lymph node status (supplementary Fig. 1i, n = 117, p = 0.00021), in ER positive tumors
(supplementary Fig. 1j, n = 183, p = 0.003), in HER2 negative tumors (supplementary Fig. 1k, n = 199, p = 
0.001) and in tumors with a low proliferation rate (Ki-67 ≤ 14% ) (supplementary Fig. 1l, n = 128, p = 
0.001). No signi cant correlations between the amount of BATMs and OS were seen in in the respective
other subgroups (data not shown).
In the subgroup analysis, a high amount of BTSMs was a negatively associated with OS in the subgroup
of patients aged older than 50 years (supplementary Fig. 2a, n = 180, p = 0.029), in Luminal A-like tumors
(supplementary Fig. 2b, n = 138, p = 0.046), in multifocal and multicentric tumors (supplementary Fig. 2c,
n = 111, p = 0.026), in tumors smaller than 2 cm in size (supplementary Fig. 2d, n = 155, p = 0.031), in BC
patients with negative lymph node status (supplementary Fig. 2e, n = 131, p = 0.029), in ER positive
tumors (supplementary Fig. 2f, n = 197, p = 0.034), in HER2 negative tumors (supplementary Fig. 2 g, n = 
219, p = 0.026) and in tumors with a low proliferation rate (Ki67 ≤ 14% ) (supplementary Fig. 2 h, n = 139,
p = 0.039). No signi cant correlations between the amount of BTSMs and OS were seen in the respective
other subgroups (data not shown).
Only BATMs but not BTSMs were negatively associated with DFS
In the overall patient cohort, the BATM-high subgroup showed a signi cantly impaired DFS compared to
patients with low amounts of BATMs (median DFS 5.35 years in the BATM-high (n = 50) vs. 9.53 years in
the BATM-low (n = 170) population, HR = 1.800, p = 0.032, Fig. 2c). There was no signi cant association
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of the amount of BTSMs with DFS, neither in the overall cohort (HR = 1.285 p = 0.431, Fig. 2d), nor in a
subgroup analysis (data not shown).
A subgroup analysis revealed that BATMS were negatively associated with DFS in the subgroups of
patients aged older than 50 years (supplementary Fig. 1m, n = 164, p = 0.015) and in patients with
unifocal tumors (supplementary Fig. 1n, n = 117, p = 0.016). No signi cant correlations between the
amount of BATMs and DFS were seen in the respective other subgroups (data not shown).
BATMS were independently associated with OS in BC
Univariate COX regression analysis showed that the BATMs subgroup (p = 0.001, HR = 2.483, 95%CI:
1.474–4.182), the BTSMs subgroup (p = 0.025, HR = 2.445, 95%CI: 1.117–5.354), the molecular subtype
(p = 0.03, HR = 1.213, 95%CI :1.081–1.444), grading (p = 0.003, HR = 1.763, 95%CI: 1.056–2.945), tumor
size (p = 5.57E-13, HR = 2.064, 95%CI: 1.695–2.513), axillary lymph node status (p = 0.002, HR = 1.859,
95%CI: 1.256–2.749) and ER status (p = 0.026, HR = 0.589, 95%CI: 0.369–0.940) were signi cantly
associated with OS (Table 2).
Multivariate analysis was performed in three different models. All models included the univariate
signi cant parameters age, molecular subtype, grading, tumor size and axillary lymph node status.
Multivariate analysis model 1 was performed including BTSMs but without BATMs, to determine if
BTSMs were independently associated with OS in the whole patient cohort. Multivariate model 2 was
performed including BATMs but without BTSMs, to determine if BATMs were independently associated
with OS in the whole patient cohort. Multivariate analysis model 3 was performed with both BATMs and
BTSMs, to determine if BATMs, BTSMs or both were independently associated with OS when both
subtypes of macrophages were considered. As shown in supplementary table 1, the multivariate COX
regression analysis model 1 revealed that tumor size (p = 0.001, HR = 1.873, 95%CI: 1.304–2.689) was
independently associated with OS, but BTSMs were not. The multivariate COX regression analysis model
2 revealed that BATMs (p = 0.002, HR = 4.259, 95%CI: 1.666–10.887) and tumor size (p = 0.001, HR = 
1.847, 95%CI: 3.113-1093.217) were independently associated with OS. The multivariate COX regression
analysis model 3 also showed that BATMs (p = 0.004, HR = 4.464, 95%CI: 1.624–12.269) and tumor size
(p = 0.001, HR = 1.827, 95%CI: 1.269–2.631) were independently associated with OS. So even when
BTSMs were taken into consideration, BATMs remained associated with OS of BC patients (Table 2).
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Table 2
Univariate and multivariate Cox regression analyses of OS including various prognostic parameters in
patients with BC
  Univariate analysis Multivariate analysis
model 3 (with both BATM
and BTSM)
  p HR 95% CI p HR 95% CI




Molecular subtype (LuA-like vs.LuB-like































PR status (PR- vs. PR+) 0.088 0.697 0.461–
1.054
n.i. n.i. n.i.
HER2 status (HER2- vs. HER2+) 0.079 1.667 0.942–
2.952
n.i. n.i. n.i.













Multivariate analysis model 3 was performed with both BATMs and BTSMs, to determine if BATMs,
BTSM or both were independently associated with OS when both subtypes of macrophages were
considered. ER, Estrogen receptor; PR, Progesterone receptor; HER2, Human Epidermal growth factor
receptor 2; LuA-like, Luminal A-like; LuB-like, Luminal B-like; TNBC, Triple negative breast cancer, HER2
Lu-like, HER2 ampli ed Luminal -like; HER2 nonLu like, HER2 ampli ed non luminal-like; BATMs,
Breast adipose tissue macrophages; BTSMs, Breast tumor-stroma macrophages; HR hazard ratio, CI,
con dence interval; n.i., not included in multivariate model as p > 0.05 in univariate analysis; *,
signi cant (p-value < 0.05).
 
BATMs were independently associated with DFS in BC
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Univariate COX regression analysis showed that the BATMs subgroup (p = 0.035, HR = 1.800, 95%CI:
1.042–3.108), tumor grade (p = 0.03, HR = 1.669, 95%CI: 1.050–2.654), tumor size (p = 0.002, HR = 1.493,
95%CI: 1.159–1.922) and lymph node status (p = 0.01, HR = 1.696, 95%CI: 1.137–2.528) were
independently associated with DFS a in our BC cohort (Table 3). BTSMs was not associated with DFS in
the univariate analysis.
The multivariate analysis included the parameters age, grading, tumor size, axillary lymph node status
and the BATM subgroup. As shown in Table 3, the multivariate COX regression analysis revealed that the
BATM subgroup (p = 0.005, HR = 3.240, 95%CI: 1.423–7.378), grading (p = 0.043, HR = 1.825, 95%CI:
1.018–3.271) and tumor size (p = 0.011, HR = 1.646, 95%CI: 1.120–2.418) were independently associated
with DFS in patients with BC (Table 3).
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Table 3
Univariate and multivariate Cox regression analyses of DFS including various prognostic parameters in
patients with BC
  Univariate analysis Multivariate analysis
  p HR 95% CI p HR 95% CI




Molecular subtype (LuA-like vs.LuB-like
























ER status (ER- vs. ER+) 0.771 0.926 0.550–
1.557
n.i. n.i. n.i.
PR status (PR- vs. PR+) 0.249 1.291 0.836–
1.994
n.i. n.i. n.i.
HER2 status (HER2- vs. HER2+) 0.511 1.228 0.666–
2.262
n.i. n.i. n.i.









BTSMs (Low vs. High) 0.432 1.285 0.687–
2.403
n.i. n.i. n.i.
ER, Estrogen receptor; PR, Progesterone receptor; HER2, Human Epidermal growth factor receptor 2;
LuA-like, Luminal A-like; LuB-like, Luminal B-like; TNBC, Triple negative breast cancer, HER2 Lu-like,
HER2 ampli ed Luminal -like; HER2 nonLu like, HER2 ampli ed non luminal-like; BTAMs, Breast
adipose tissue macrophages; BTSMs, Breast tumor-stroma macrophages; HR hazard ratio, CI
con dence interval, n.i., not included in multivariate model, as p > 0.05 in univariate analysis, *,
signi cant (p-value < 0.05).
 
BATMs correlated negatively to EP3 expression and a combination of both parameters identi ed a
subgroup with extremely poor OS and DFS
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The quantity of BATMs (continuous variable) correlated negatively to the EP3 expression quanti ed by
the IRS (continuous variable, spearman r = − 0.1977, p = 0.0034, Fig. 3a). In the BATM-high subgroup, the
EP3 expression was signi cantly lower than in the BATM-low subgroup (p = 0.00392) (Fig. 3b). Similarly,
when categorizing EP3 in an EP3-high (IRS > 1) and an EP3-low (IRS ≤ 1) expressing subgroup, there were
higher quantities of BATMs in the EP3-low than in the EP3-high subgroup. (p = 0.0322, Fig. 3c).
Comparing both categorized variables (BATM-high and -low with EP3-high and -low), a correlation of only
borderline signi cance could be found (p = 0.051, Table 1). No correlations between EP3 expression and
the quantity of BTSMs could be shown (data not shown).
Consistent with the previous study by our team (in which patients with DCIS were not excluded) (24), OS
and DFS were superior in invasive BC patients with high expression of EP3 compared to patients with low
EP3 expression (OS: p = 0.000019, HR = 0.407, 95%-CI 0.266–0.623), Fig. 3d and DFS: p = 0.000086, HR = 
0.426, 95%-CI 0.274–0.660, Fig. 3e). We de ned four subgroups using combinations of the categorized
variables EP3-high/-low and BATM-high/low. Doing so, we could identify a subgroup with an extremely
poor prognosis: patients in the subgroup “EP3-low/BATM-high” (n = 20) showed the worst survival rates -
median OS 2.31 years and median DFS 2.18 years – compared to the group “EP3-high/BATM-low” (n = 
124) with the best prognosis (OS: median OS 11.42 years, p = 0.000002, Fig. 3f and table 4, part A; DFS:
median DFS NR, p = 0.000005, Fig. 3 g and table 4, part A). In other words, patients in the “EP3-low
/BATMs-high” subgroup had a 1.756 times higher mortality risk and 1.922 times higher recurrence risk
than patients in the favorable “EP3-high/BATM-low” subgroup (table 4 part A). Moreover, the association
of BATMs with OS was different considering EP3 expression: in the BATMs-high subgroup, EP3-low-
expressing patients had a 1.647 times higher mortality risk (p = 0.023) and 2.107 times higher recurrence
risk (p = 0.004) than EP3-high-expressing patients (table 4, part B). But EP3 was also associated with
survival in the BATM-low subgroup, where EP3-low-expressing patients had a 1.511 times higher mortality
risk (p = 0.01) and 1.405 times higher recurrence risk (p = 0.028) than EP3-high-expressing patients (table
4, part C). Interestingly, BATMs on the other hand did not modify the positive prognostic association of a
high EP3-expression: in the EP3-high subgroup, OS and DFS were not signi cantly different between
BATM-low and BATM-high patients (OS: p = 0.059; DFS: p = 0.326, table 4 part D). Only in the EP3-low
subgroup, BATMs were signi cantly correlated to OS and the BATM-high subgroup had a 2.722 times
higher mortality risk (p = 0.007) and a 4.049 times higher recurrence risk (p = 0.002) than the BATM-low
subgroup (table 4, part E).
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Table 4
BC survival analysis using a combination of the prognostic factors EP3 and BATMs
  OS% p value HR 95% CI DFS% p value HR 95% CI
A.                
EP3 high + 
BATM low
83.1       77.4      
EP3 high + 
BATM high
70.0 0.059 2.128 0.973–
4.658




58.1 0.01* 1.511 1.102–
2.070




35.0 0.000002* 1.756 1.391–
2.217
60.0 0.000005* 1.922 1.453–
2.544
B.                
BATM high + 
EP3 high
70.0       66.7      
BATM high + 
EP3 low
35.0 0.023* 1.647 1.070–
2.536
60.0 0.004* 2.107 1.264–
3.513
C.                
BATM low + 
EP3 high
83.1       77.4      
BATM low + 
EP3 low
58.1 0.01* 1.511 1.102–
2.070
60.5 0.028* 1.405 1.037–
1.902
D.                
EP3 high + 
BATM low
83.1       77.4      
EP3 high + 
BATM high
70.0 0.059 2.128 0.973–
4.658
66.7 0.326 1.437 0.697–
2.962
E.                
EP3 low + 
BATM low
58.1       60.5      
EP3 low + 
BATM high
35.0 0.007* 2.722 1.321–
5.609
60.0 0.002* 4.049 1.665–
9.847
BATMs, Breast adipose tissue macrophage; EP3, prostaglandin E receptor 3 ; OS, Overall survival; DFS,
Disease-free survival; p, p value; HR, hazard ratio; CI con dence interval; *,signi cant (p-value < 0.05).
Discussion
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In this study of 298 sporadic invasive BC cases, we could demonstrate that the abundance of
macrophages not only in the tumor-stroma (BTSMs) but also in the breast adipose tissue (BATMs) was
negatively associated with OS. We could also show that BATMs were negatively associated with DFS.
Furthermore, BATMs were an independent prognostic parameter for both OS and DFS in BC in a
multivariate analysis while BTSMs were not. This suggests that local breast adipose tissue might be
associated with BC outcome.
The relationship between adipocytes in adipose tissue of obese BC patients and macrophages has been
well documented in recent years (34, 45). However, our study did not focus on adipose tissue due to
obesity nor did we include obese patients only – it aimed to analyze the role of the adipose tissue right in
the breast that is also present in lean BC patients. We, therefore observed for the  rst time in the current
study that local adipose tissue might have a negative association with BC survival, if elevated rates of
macrophages occur in it. BATMs might initiate or enhance tumorigenic immune effects in BC.
However, up to now we could not reveal where the BATMs originate from. Possible theories are: (i) BATMs
are derived from BTSMs that migrate to adipose tissue by chemotaxis; (ii) BATMs are derived from
monocytes that migrate into the breast adipose tissue due to adipocyte-derived adipokines and
differentiate into a speci c adipose-tissue associated macrophage phenotype or (iii) BATMs are derived
from both sources named above.
In our study we found a strong correlation between the two types of macrophages (BATMs vs. BTSMs),
which might lead to the conclusion that BTSMs are the source of BATMs. However, although the quantity
of BATMs and BTSMs correlated strongly, their associations with clinical parameters and outcome were
not the same. This favors the theory of an origin of the BATMs from the blood monocyte/macrophage
cell lineage. Most probably, BATMs are not derived from a single but from both sources. In the condition
of obesity, the continuous  ow and accumulation of macrophages from the blood circulation to the
adipose tissue is an important process that initiates the chronic in ammation in the adipose tissue of
obese individuals (46). However, without the condition of obesity, it is still not known if a similar adipose
tissue-macrophage crosstalk exists. Further research might help to answer this question.
We further found that EP3 expression was negatively correlated to BATM quantity and that the
association of BATMs with survival outcomes was different considering EP3 expression. EP3 has shown
a positive prognostic association with BC survival in our previous study (24), similar to EP1 (25), but
contrary to the negative effects of EP2 and EP4 (21, 23). However, the positive prognostic role of EP3
could not be explained by tumor cell biology, which resulted in the hypothesis that EP3-mediated effects
in BC might be modulated by other aspects, like immunological factors in the tumor environment (47). As
the present study now shows how EP3 is correlated to BATMs, EP3 might be involved in the regulation of
the occurrence or the phenotype of BATMs in BC, which might explain the observed positive association
of EP3 with BC survival. Intriguingly, a recent study pointed out that EP3 could induce an Interleukin-13
(IL-13)-mediated polarization of macrophages from a pro-in ammatory to a pro-reparative phenotype
during liver repair (48). Similar mechanisms of EP3 in uencing macrophage polarization, e. g. reducing
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the pro-tumorigenic effect of BATMs by converting or alternating the polarized phenotype, might exist in
BC. Our further studies aim to clarify how EP3 might regulate BATMs in BC.
In contrast to BATMs, the amount of BTSMs was particularly associated with the BC molecular subtype
in our study. In TNBC, BTSMs were highest among all  ve molecular subtypes. Similarly, BTSMs were
associated with a negative ER status and ki-67 rates > 14%. In conclusion, high amounts of BTSMs were
associated with aggressive clinical features. Especially in TNBC, options for targeted therapies are in the
focus of recent research to improve the prognosis of this patient subgroup (49). BTSMs might offer an
option for a future targeted therapy and might additionally serve as prognostic factor to stratify patients’
risk and to choose the appropriate therapy (27, 50, 51).
We found a signi cant association of BATMs and BTSMs with the prognosis of BC patients not only in
the overall cohort, but also in different subgroups. This indicates that the prognostic role of macrophages
can differ dependently on different tumor context. This supports the thesis that the development of BC is
not only controlled by a single molecule abnormality, but also by the interplay between BC cells and the
whole tumor microenvironment (TME) (52). Besides the number of tumor-associated macrophages, their
polarization is also relevant for tumor development (53–55). As research on the polarization state of
macrophages has become more abundant and in-depth, recent studies have shown that their occurrence
in tumors and their in uence on tumor development is more complicated than initially thought.
Macrophages in the tumor microenvironment are not limited to the M1 or M2 phenotype, but can reside in
between or outside the spectrum (56). In white adipose tissue during obesity, a complex mixture of M1
and M2 macrophages phenotypes can be observed (57). This indicates that also BATMs cannot be
classi ed using the simple dual M1/M2 model. The removal of all macrophage populations, regardless
of their polarization status, has remarkable in uence: The occurrence of primary and metastatic tumors
was signi cantly reduced due to macrophage depletion (56). However, that study did not distinguish
between BTSMs and BATMs. So, in the context of BC immunotherapy, enhancing the understanding of
the speci c roles of BATMS and BTSMs, respectively, might seem to be as or even more important than
characterizing their phenotype as M1 or M2. To deeply understand how BATMs might be involved in BC
development and to evaluate prevention and treatment strategies thoroughly, a clear analyzation of the
BATMs subgroup is crucial.
Conclusion
An abundance of BATMs in BC was an independent and highly signi cant prognostic factor for an
impaired OS and DFS. The quantity of BATMs correlated signi cantly with the amount of BTSMs,
however, BTSMs were not an independent prognostic factor for neither OS nor DFS. The amount of
BTSMs, in contrast, correlated signi cantly with the molecular subtype and was especially high in TNBC.
Therefore, it is essential to keep in mind that research on the role of macrophages in BC should not just
focus on M1 or M2 polarization, but also on the exact localization of macrophages in the TME. We could
demonstrate that the subpopulations of BTSMs and BATMs might affect the overall development of BC
together but each subpopulation in a different way. As their quantity is signi cantly related to each other,
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both subgroups seem to depend on each other. Most importantly, our  ndings suggest that breast
adipose tissue might contribute to the aggressiveness of BC via BATMs. Targeting BATMs might be a
promising strategy in future BC therapies.
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BATMs Breast Adipose Tissue Macrophages
BC Breast cancer
BMI Body mass index
BTSMs Breast Tumor-Stroma Macrophages
CI Con dence interval
CLS Crown-like structures
DCIS Ductal carcinoma in Situ
DFS Disease free survival
EP1 Prostaglandin E receptor 1
EP2 Prostaglandin E receptor 2
EP3 Prostaglandin E receptor 3
EP4 Prostaglandin E receptor 4
ER Estrogen receptor
HER2 Human epidermal growth factor receptor 2
HER2 Lu-like HER2 ampli ed Luminal -like


















RFS Relapse free survival
ROC-curve Receiver operating characteristic curve
TAMs Tumor-associated macrophages
TME Tumor microenvironment
TNBC Triple-negative breast cancer
VLD Very low density
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